Abstract
(4-Phenoxyphenylsulfonyl)methylthiirane (compound 1) is a highly selective and potent inhibitor of gelatinases that shows considerable promise in animal models for cancer and stroke. The metabolism of compound 1 was investigated in mice, following intraperitoneal administration at 100 mg/kg. Eight metabolites were identified in plasma and urine. The primary routes of metabolism of 1 were hydroxylation at the para-position of the terminal phenyl ring, hydroxylation at the α-methylene to the sulfonyl, which lead to the generation of a sulfinic acid, and cysteine conjugation of the thiirane ring. The cysteine adducts arose through addition of glutathione to the thiirane ring. The molecule is extensively metabolized and excreted in mice, yet it exhibits activity in vivo.
| Original language | English |
|---|---|
| Pages (from-to) | 187-196 |
| Number of pages | 10 |
| Journal | Chemical Biology and Drug Design |
| Volume | 71 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2008 |
Funding
| Funders | Funder number |
|---|---|
| National Institute of General Medical Sciences | T32GM075762 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Gelatinase inhibitor
- Glutathione adduct
- Metabolism
ASJC Scopus subject areas
- Biochemistry
- Molecular Medicine
- Pharmacology
- Drug Discovery
- Organic Chemistry
Fingerprint
Dive into the research topics of 'Metabolism of (4-phenoxyphenylsulfonyl)methylthiirane, a selective gelatinase inhibitor'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver